sumatriptan
A retrospective pharmacoeconomic model suggested that the       cost-effectiveness of subcutaneous sumatriptan versus subcutaneous       dihydroergotamine depended on which outcome measure was of greatest interest.
A retrospective pharmacoeconomic model suggested that the       cost-effectiveness of subcutaneous  @SUBJECT$   @PREDICAT$  subcutaneous        @OBJECT$  depended on which outcome measure was of greatest interest.